Hospital Research Receives Trial of the Year Award


A study led by Barbara Schmidt, M.D., M.Sc., Division of Neonatology, was honored with the Trial of the Year award by The Society for Clinical Trials (SCT) and Project Important Achievements of Clinical Trials (Project ImpACT).

The study confirms that caffeine therapy for apnea of prematurity improves the rate of survival without neurodevelopmental disability.

For more than 30 years, caffeine and similar drugs have been used to regulate the breathing of very preterm babies, but without sufficient knowledge of the possible benefits and risks. This study provides evidence that the benefits of caffeine therapy outweigh the possible risks for up to two years after very pre-term birth.

The SCT and Project ImpACT selected Dr. Schmidt’s study because it is the first randomized control trial showing an important health effect from this intervention, and uses sound methodology that was likely to be right. In addition, it presents findings that can be applied widely, not just to developed world settings, confirms the value of proper evaluations of medical interventions, and demonstrates courage by testing an established therapy.

Dr. Schmidt was announced as the recipient of the SCT/ImpACT Trial of the Year award at the SCT’s 29th Annual Meeting on International Clinical Trials Day on May 20.